Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 12/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846508 | 0.93 | CCR3 (0.56) | CCR1DRD2DRD3DRD4CCR3 | |
| SCHEMBL5847174 | 0.91 | DRD2 (0.57) | CCR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL5848271 | 0.91 | SIGMAR1 (0.53) | CCR1DRD2DRD3DRD4CCR3 | |
| SCHEMBL5846506 | 0.82 | DRD2 (0.50) | CCR1DRD2DRD3DRD4CCR3 | |
| SCHEMBL5848902 | 0.80 | OPRL1 (0.54) | CCR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL5847342 | 0.74 | CCR1 (0.53) | CCR1DRD2DRD3DRD4CCR3 | |
| SCHEMBL5846884 | 0.73 | SIGMAR1 (0.56) | DRD2HTR1AHTR7 | |
| SCHEMBL20248960 | 0.71 | DRD2 (0.68) | CCR1DRD2DRD3DRD4HTR1A | |
| SCHEMBL8416503 | 0.71 | HTR1A (0.61) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL8416472 | 0.71 | KDM4E (0.61) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0721455-B9 | TETRAHYDROPYRIDINE-(OR 4-HYDROXYPIPERIDINE)ALKYLAZOLES HAVING AN AFFINITY FOR SIGMA AND/OR 5HT1A RECEPTORS | ESTEVE LABOR DR (ES) | 2005-04-20 | — | — | EP | claimed |
| EP-1097698-B1 | UTILIZATION OF DERIVATIVES OF TETRAHYDROPYRIDINES (OR 4-HYDROXYPIPERIDINES)-BUTYLAZOLS IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF PAIN | ESTEVE LABOR DR (ES) | 2003-05-07 | — | — | EP | claimed |
| EP-0721455-B1 | TETRAHYDROPYRIDINE-(OR 4-HYDROXYPIPERIDINE)ALKYLAZOLES HAVING AN AFFINITY FOR SIGMA AND/OR 5HT1A RECEPTORS | ESTEVE LABOR DR (ES) | 2002-12-11 | — | — | EP | claimed |
| EP-1097698-A2 | UTILIZATION OF DERIVATIVES OF TETRAHYDROPYRIDINES (OR 4-HYDROXYPIPERIDINES)-BUTYLAZOLS IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-09 | — | — | EP | claimed |
| EP-0939632-B1 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | LILLY CO ELI (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-0721455-B9 | TETRAHYDROPYRIDINE-(OR 4-HYDROXYPIPERIDINE)ALKYLAZOLES HAVING AN AFFINITY FOR SIGMA AND/OR 5HT1A RECEPTORS | ESTEVE LABOR DR (ES) | 2005-04-20 | — | — | EP | disclosed |
| US-6610680-B1 | Administering as adjuncts in heart failure or as antithrombotic agents, treatment of obsessive-compulsive disorder, aggressive disorders, depression and anxiety | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-0721455-B1 | TETRAHYDROPYRIDINE-(OR 4-HYDROXYPIPERIDINE)ALKYLAZOLES HAVING AN AFFINITY FOR SIGMA AND/OR 5HT1A RECEPTORS | ESTEVE LABOR DR (ES) | 2002-12-11 | — | — | EP | disclosed |
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | BRUNS ROBERT F (US) | 2002-04-25 | — | — | US | disclosed |
| US-6232329-B1 | POSSESSING THERAPEUTIC ACTIVITY FOR THE TREATMENT OF ANXIETY, PSYCHOSIS, EPILEPSY, CONVULSION, MOTORICITY PROBLEMS, AMNESIA, CEREBROVASCULAR DISEASES OR SENILE DEMENTIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-15 | — | — | US | disclosed |
| US-6204260-B1 | 2-(AZETIDIN-2-ON-1-YL)ACETIC ACID DERIVATIVES | ELI LILLY AND COMPANY | 2001-03-20 | — | — | US | disclosed |
| US-5731331-A | Tetrahydropyridine-(or 4-hydroxypiperidine) alkylazoles | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1998-03-24 | — | — | US | disclosed |
| WO-1996004287-A1 | TETRAHYDROPYRIDINE-(OR 4-HYDROXYPIPERIDINE)ALKYLAZOLES HAVING AN AFFINITY FOR SIGMA AND/OR 5HT1A RECEPTORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | CCR1 1565/4885DRD2 316/4885DRD3 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.